pubmed-article:17478472 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C0920317 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C0021755 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C0456081 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C0439852 | lld:lifeskim |
pubmed-article:17478472 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
pubmed-article:17478472 | pubmed:issue | 7 | lld:pubmed |
pubmed-article:17478472 | pubmed:dateCreated | 2007-6-25 | lld:pubmed |
pubmed-article:17478472 | pubmed:abstractText | New treatments that inhibit the cytokines tumour necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1) in the treatment of rheumatoid arthritis have proven clinical effect against placebo and methotrexate (MTX) in several clinical trials in early and late-stage disease and different severity groups. Since there are no head-to-head randomized controlled trials directly comparing the currently available treatments, etanercept, adalimumab, infliximab or anakinra, we perform a meta-analysis that adjusts for differences between study characteristics, and allows indirect comparisons between treatments. | lld:pubmed |
pubmed-article:17478472 | pubmed:language | eng | lld:pubmed |
pubmed-article:17478472 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17478472 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17478472 | pubmed:month | Jul | lld:pubmed |
pubmed-article:17478472 | pubmed:issn | 1462-0324 | lld:pubmed |
pubmed-article:17478472 | pubmed:author | pubmed-author:NixonRR | lld:pubmed |
pubmed-article:17478472 | pubmed:author | pubmed-author:BrennanAA | lld:pubmed |
pubmed-article:17478472 | pubmed:author | pubmed-author:BansbackNN | lld:pubmed |
pubmed-article:17478472 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17478472 | pubmed:volume | 46 | lld:pubmed |
pubmed-article:17478472 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17478472 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17478472 | pubmed:pagination | 1140-7 | lld:pubmed |
pubmed-article:17478472 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:meshHeading | pubmed-meshheading:17478472... | lld:pubmed |
pubmed-article:17478472 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17478472 | pubmed:articleTitle | The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. | lld:pubmed |
pubmed-article:17478472 | pubmed:affiliation | MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge CB2 2SR, UK. richard.nixon@mrc-bsu.cam.ac.uk | lld:pubmed |
pubmed-article:17478472 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17478472 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:17478472 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:17478472 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17478472 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17478472 | lld:pubmed |